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Abstract
Background: Q fever is caused by the intracellular bacterium Coxiella burnetii. Initial infection can present as acute
Q fever, while a minority of infected individuals develops chronic Q fever endocarditis or vascular infection months
to years after initial infection. Serology is an important diagnostic tool for both acute and chronic Q fever. However,
since immunosuppressive drugs may hamper the humoral immune response, diagnosis of Q fever might be blurred
when these drugs are used.
Case presentation: A 71-year-old Caucasian male was diagnosed with symptomatic acute Q fever (based on
positive C. burnetii PCR followed by seroconversion) while using anti-tumor necrosis factor-α (anti-TNFα) drugs
for rheumatoid arthritis (RA). He was treated for two weeks with moxifloxacin. After 24 months of follow-up, the
diagnosis of probable chronic Q fever was established based on increasing anti-C. burnetii phase I IgG antibody
titres in a immunocompromised patient combined with clinical suspicion of endocarditis. At the time of chronic Q
fever diagnosis, he had been treated with anti B-cell therapy for 16 months. Antibiotic therapy consisting of 1.5 years
doxycycline and hydroxychloroquine was started and successfully completed and no signs of relapse were seen
after more than one year of follow-up.
Conclusion: The use of anti-TNFα agents for RA in the acute phase of Q fever did not hamper the C. burnetii-specific
serological response as measured by immunofluorescence assay. However, in the presented case, an intact humoral
response did not prevent progression to probable chronic C. burnetii infection, most likely because essential cellular
immune responses were suppressed during the acute phase of the infection. Despite the start of anti-B-cell therapy
with rituximab after the acute Q fever episode, an increase in anti-C. burnetii phase I IgG antibodies was observed,
supporting the notion that C. burnetii specific CD20-negative memory B-cells are responsible for this rise in antibody
titres.
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Background
Q fever is caused by the intracellular growing bacterium
Coxiella burnetii [1]. Acute Q fever is a (self-limiting) fe-
brile illness, but can present as pneumonia or hepatitis.
Chronic Q fever presents most often as an endovascular
infection, i.e. endocarditis or mycotic aneurysm or in-
fected vascular graft, which has a high mortality if left
untreated [2,3]. Risk factors are underlying valvular de-
fects, or pre-existing vascular aneurysm or prosthesis.
Immunosuppression is another stated risk factor for
chronic Q fever, as some immunosuppressive drugs de-
crease protective cellular responses against intracellular
growing bacteria. This risk factor has thus far been
poorly documented, but recently we confirmed that pa-
tients with rheumatoid arthritis (RA) using immunosup-
pressive drugs are indeed at increased risk of developing
chronic Q fever [4].
Clinical signs of C. burnetii infection are often nonspe-
cific, and the diagnosis of acute or chronic Q fever is
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heavily based on measurement of antibody titres [5,6],
complemented by the direct detection of the micro-
organism by polymerase chain reaction (PCR) [7,8].
Serologic criteria for Q fever consist of measurement of
antibodies against the two antigenic forms of C. burnetii,
phase I and II organisms, with high anti-C. burnetii phase
I IgG titres - in the absence of acute Q fever – pointing to
a chronic infection. The appropriate cut-off titre that dif-
ferentiates it from a past cleared infection is debated; cur-
rently proposed cut-offs are 1:1,024 or 1:1,600 [6,9].
The diagnosis of Q fever in hosts on immunosuppres-
sive drugs may be complicated, because these drugs can
inhibit antibody responses and therefore hamper correct
diagnosis based on serologic results. Also the immune-
mediated disease itself, for which these drugs are pre-
scribed, may contribute to inadequate immune responses
to infection [10,11].
Here we present a case history of a patient with RA
who had an episode of acute Q fever while being treated
with anti-tumor necrosis factor-α (anti-TNFα) medica-
tion, and who developed probable chronic Q fever over
the subsequent two years while using the anti-B-cell
monoclonal antibody rituximab. The case highlights the
importance of cellular and humoral immune response
modifying agents in the natural course of C. burnetii in-
fections and the possible pitfalls of the use of serological
methods to detect the stage of disease.
Case presentation
Acute Q fever
In May 2009, during the Dutch Q fever epidemic, a 71-
years-old rheumatoid factor and anti-CCP positive RA
patient living in the Q fever high incidence area, pre-
sented with 8 days of fever and a non-productive cough.
He was receiving anti-rheumatic treatment including
etanercept (an anti-tumor necrosis factor-α [anti-TNFα]
agent) and prednisone. He had a history of atrial fibrilla-
tion, but no underlying valvulopathy. Physical examination
and a chest X-ray were compatible with a pulmonary infil-
trate. No murmurs were heard upon cardiac auscultation.
Laboratory investigations revealed increased C-reactive
protein (CRP, 285 mg/L), a normal leukocyte count
(5.2×109/L) and normal values for renal function and
liver enzymes. PCR (real-time PCR targeting the IS1111a
insertion element [12]) for C. burnetii on plasma turned
out to be positive. However, serology (immunofluores-
cence assay [IFA, Focus Diagnostics, Cypress, USA]) was
negative for IgM as well as for IgG against phase I and II
Coxiella burnetii. The diagnosis of acute Q fever was
made and treatment with moxifloxacin 400 mg daily for
14 days was started. Two weeks later, seroconversion was
observed with anti-phase I and II IgM titres of 1:4096 and
1:16384 respectively.
Diagnosis and treatment of probable chronic Q fever
After quick recovery, the patient was followed-up to
monitor for possible progression to chronic Q fever. Dur-
ing this period, the anti-rheumatic treatment had been
switched by the rheumatologist from etanercept to adali-
mumab (another anti-TNFα agent), and subsequently –
8 months after the acute Q fever episode – to rituximab.
The latter, an anti-CD20 anti B-cell monoclonal antibody,
had resulted in adequate suppression of the rheumatic
activity.
As can be seen in Figure 1, anti-phase I IgG antibodies
titres had not decreased below 1:1024 after more than one
year, and continued to increase to 1:4096 at 24 months,
suggesting development of chronic Q fever. At that mo-
ment, the patient had complaints of general fatigue but no
fever, night-sweats or cardiac problems. On physical
examination, however, a grade 2/6 aortic systolic murmur
was audible. Transesophageal echocardiography (TEE)
showed no signs of endocarditis, but an echogenic mitral
annulus and a trace of mitral valve insufficiency. Labora-
tory investigation showed an ESR 40 mm/hr with CRP <
2 mg/L. PCR for C. burnetii in plasma was repeatedly
negative. Abdominal ultrasound did not reveal an aortic
aneurysm. Positron-emission tomography (PET)-scanning
showed hilar lymphadenopathy but no other abnormalties.
Endobronchial biopsy of the hilar lymph nodes was PCR
negative for C. burnetii and showed no signs of malig-
nancy. Because of the increasing anti-phase I IgG titres in
this immunocompromised patient, in combination with
nonspecific complaints and the new cardiac murmur , the
diagnosis of ‘probable chronic Q fever’ was made [13] and
the patient was started on doxycycline 200 mg daily com-
bined with hydroxychloroquine 200 mg three times daily
for 1.5 years. Intermittent courses with rituximab were
continued as anti-rheumatic treatment, in combination
with azathioprine. During antibiotic treatment, the anti-
phase I IgG titres decreased from 1:8192 to 1:1024. The
patient experienced improvement from his fatigue. After
1.5 years treatment, PET-scanning and TEE were un-
changed. After discontinuation of antibiotics, the sero-
logical and clinical follow-up was pursued and is still
continuing, with no relapse after more than one year.
Discussion
We report on an immunocompromised patient, followed-
up from the start of a symptomatic acute Q fever episode
to the development and treatment of probable chronic Q
fever. Our case illustrates three interesting aspects of diag-
nosis and treatment of Q fever in an immunocomprom-
ised host. First, we noticed that, despite the presence of
RA and use of anti-TNFα agents, the humoral response
to the initial C. burnetii infection was not impaired. Sec-
ondly, in spite of adequate treatment, the acute Q fever
progressed to probable chronic Q fever endocarditis,
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which suggests incomplete clearance of the infection
during the acute stage. Finally, the increase in phase I
IgG titres, which serves as a marker for chronic Q fever,
occurred under treatment with anti B-cell immunother-
apy which was started after the acute Q fever episode.
In the presented case, a definite diagnosis of chronic Q
fever could not be made. C. burnetii DNA was not detected
in blood on several occasions and echocardiography did
not show major signs of endocarditis. Nevertheless, chronic
Q fever was clinically highly suspected. The patient was
followed-up after acute Q fever, and we observed that
the antibody titres were falling after they had peaked
following the acute Q fever episode, only to rise again
after 18 months. This increase in antibody titres was ac-
companied by aspecific complaints of fatigue and a
newly diagnosed cardiac murmur. According to the
Dutch guidelines, this was a diagnosis of probable
chronic Q fever [13], and the patient received antibiotic
treatment as considered appropriate.
Interestingly, we observed a normal antibody response
in the acute phase of the Q fever infection under anti-
TNFα therapy. This is in line with previous studies
which have shown that anti-TNFα therapy does not pre-
vent serologic responses to influenza vaccination [14,15],
although titres may be somewhat lower. Clearly, in our
case, this normal antibody response did not prevent the
development of persistent C. burnetii infection, as
complete clearance might depend more on cellular im-
mune responses.
Indeed, to constrain intracellular C. burnetii infections,
a cellular immune response is crucial and TNFα is a key
cytokine in this response. In-vitro studies showed that
TNFα mediates interferon-gamma induced intracellular
killing of C. burnetii in monocytes through apoptosis
[16]. TNF knock-out mice infected with C. burnetii develop
early bactaeremia and severe heart lesions [17]. Infection
risk due to decreased cellular immunity in anti-TNFα
treated patients, has been shown for other intracellular
infections, most notably Mycobacterium tuberculosis,
but also Listeria monocytogenes and Salmonella enterica,
and for herpesviridae [18-21].
Rituximab, an anti-CD20 monoclonal antibody, is used
for the treatment of RA patients failing on TNFα
blockers. Rituximab depletes circulating CD20-positive
B-cells for a period of six to nine months [22]. As a conse-
quence, patients on rituximab therapy have an impaired
antibody response to neo-antigens. Existing plasma cells
and memory B-cells, which do not express CD20, are not
affected by rituximab [23]. During the development from
acute to chronic Q fever, there is an ongoing infection
with presumably increasing concentrations of C. burnetii
antigens. Because plasma cells do not express B-cell re-
ceptors at their surface, which makes them incapable to
respond to alterations in antigen concentrations, we
assume that the rise of anti-C. burnetii IgG titres in our
patient originated from stimulation of memory IgG B-
cells by increased concentrations of recall antigens. This
intact response to recall antigens after rituximab has been
Figure 1 Q fever serology during follow-up after acute Q fever in a patient with anti-rheumatic drugs. Serological titres of anti-Coxiella
burnetii phase I and phase II IgG (as measured by immunofluorescence assay) during follow-up after acute Q fever (t = 0) of a patient using
subsequently etanercept, adalimumab and rituximab as biological disease-modifying anti-rheumatic drugs. Rituximab was given with 7 months
intervals, each time two dosages with two weeks interval. At t = 24 the diagnosis probable chronic Q fever was established followed by anti-microbial
treatment with doxycycline and hydroxychloroquine for 1.5 years.
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observed for patients receiving vaccinations [24], but has
never been documented after natural infection.
Our results indicate that anti-C. burnetii phase I IgG
antibody titres can be used as a marker for progression
to chronic Q fever and the subsequent response to
therapy in patients in whom B-cell depleting therapy is
started after initial exposure. However, it is likely that
B-cell depleting medication during first contact with
neo-antigens of C. burnetii will seriously hamper the
development of an antibody response and the diagnosis
of Q fever based on serological titres.
Conclusions
The use of anti-TNFα agents for RA in the acute phase
of Q fever does not seem to impede the C. burnetii-spe-
cific serological response. However, in the presented
case, an intact humoral response did not prevent pro-
gression to probable chronic C. burnetii infection, most
likely because essential cellular immune responses were
suppressed in the acute phase of the infection. Even
though anti-B-cell therapy with rituximab was started
after the acute Q fever episode, an increase in anti-C.
burnetii phase I antibodies was observed, supporting the
notion that C. burnetii specific CD20-negative memory
B-cells are responsible for this rise in antibody titres.
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